Table 4.
Ongoing phase 3 trials of niraparib monotherapy or combination therapy.
| Therapy | Trial Name | Intervention | Study Population |
|---|---|---|---|
| Niraparib plus immunotherapy | FIRST (NCT03602859) |
Platinum-based chemotherapy versus platinum-based chemotherapy with adjuvant dostarlimab and maintenance dostarlimab and niraparib | Newly diagnosed advanced stage high-grade non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancers regardless of cytoreductive status |
| ENGOT-Ov42-NSGO/AVANOVA triplet (NCT03806049) |
Platinum-based chemotherapy versus niraparib-bevacizumab-dostarlimab triplet verus niraparib-bevacizumab doublet | Recurrent platinum-sensitive epithelial ovarian, fallopian tube or primary-peritoneal cancers | |
| ANITA (NCT03598270) |
Platinum-based chemotherapy with maintenance niraparib versus platinum-based chemotherapy plus atezolizumab with maintenance niraparib and atezolizumab | Recurrent platinum-sensitive epithelial ovarian, fallopian tube or primary-peritoneal cancers with known BRCA-status and less than 3 lines of chemotherapy | |
| ROCSAN (NCT03651206) |
Platinum-based chemotherapy versus niraparib monotherapy versus niraparib + dostarlimab | Metastatic or recurrent endometrial ovarian cancer or ovarian carcinosarcoma after at least 1 line of chemotherapy |